Show simple item record

dc.contributor.authorParker, CC
dc.contributor.authorColeman, RE
dc.contributor.authorSartor, O
dc.contributor.authorVogelzang, NJ
dc.contributor.authorBottomley, D
dc.contributor.authorHeinrich, D
dc.contributor.authorHelle, SI
dc.contributor.authorO'Sullivan, JM
dc.contributor.authorFosså, SD
dc.contributor.authorChodacki, A
dc.contributor.authorWiechno, P
dc.contributor.authorLogue, J
dc.contributor.authorSeke, M
dc.contributor.authorWidmark, A
dc.contributor.authorJohannessen, DC
dc.contributor.authorHoskin, P
dc.contributor.authorJames, ND
dc.contributor.authorSolberg, A
dc.contributor.authorSyndikus, I
dc.contributor.authorKliment, J
dc.contributor.authorWedel, S
dc.contributor.authorBoehmer, S
dc.contributor.authorDall'Oglio, M
dc.contributor.authorFranzén, L
dc.contributor.authorBruland, ØS
dc.contributor.authorPetrenciuc, O
dc.contributor.authorStaudacher, K
dc.contributor.authorLi, R
dc.contributor.authorNilsson, S
dc.date.accessioned2017-08-02T14:35:26Z
dc.date.issued2018-03
dc.identifier.citationEuropean urology, 2018, 73 (3), pp. 427 - 435
dc.identifier.issn0302-2838
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/756
dc.identifier.eissn1873-7560
dc.identifier.doi10.1016/j.eururo.2017.06.021
dc.description.abstractBackground In Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA) trial, radium-223 versus placebo prolonged overall survival with favorable safety in castration-resistant prostate cancer patients with symptomatic bone metastases. Long-term radium-223 monitoring underlies a comprehensive safety and risk/benefit assessment.Objective To report updated ALSYMPCA safety, including long-term safety up to 3 yr after the first injection.Design, setting, and participants Safety analyses from phase 3 randomized ALSYMPCA trial included patients receiving ≥1 study-drug injection (600 radium-223 and 301 placebo). Patients (405 radium-223 and 167 placebo) entered long-term safety follow-up starting 12 wk after the last study-drug injection, to 3 yr from the first injection. Forty-eight of 405 (12%) radium-223 and 12/167 (7%) placebo patients completed follow-up, with evaluations every 2 mo for 6 mo, then every 4 mo until 3 yr.Outcome measurements and statistical analysis All adverse events (AEs) were collected until 12 wk after the last injection; subsequently, only treatment-related AEs were collected. Additional long-term safety was assessed by development of acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS), aplastic anemia, and secondary malignancies. Data analysis used descriptive statistics.Results and limitations During treatment to 12 wk following the last injection, 564/600 (94%) radium-223 and 292/301 (97%) placebo patients had treatment-emergent AEs (TEAEs). Myelosuppression incidence was low. Grade 3/4 hematologic TEAEs in radium-223 and placebo groups were anemia (13% vs 13%), neutropenia (2% vs 1%), and thrombocytopenia (7% vs 2%). Ninety-eight of 600 (16%) radium-223 and 68/301 (23%) placebo patients experienced grade 5 TEAEs. Long-term follow-up showed no AML, MDS, or new primary bone cancer; secondary non-treatment-related malignancies occurred in four radium-223 and three placebo patients. One radium-223 patient had aplastic anemia 16 mo after the last injection. No other cases were observed. Limitations include short (3-yr) follow-up.Conclusions Final long-term safety ALSYMPCA analysis shows that radium-223 remained well tolerated, with low myelosuppression incidence and no new safety concerns.Patient summary Updated Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA) trial findings show that radium-223 remained well tolerated during treatment and up to 3 yr after each patient's first injection.
dc.formatPrint-Electronic
dc.format.extent427 - 435
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleThree-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial.
dc.typeJournal Article
dcterms.dateAccepted2017-06-13
rioxxterms.versionofrecord10.1016/j.eururo.2017.06.021
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2018-03
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfEuropean urology
pubs.issue3
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Prostate and Bladder Cancer Research
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Prostate and Bladder Cancer Research
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume73en_US
pubs.embargo.termsNot known
icr.researchteamProstate and Bladder Cancer Researchen_US
dc.contributor.icrauthorParker, Chrisen
dc.contributor.icrauthorMarsden,en
dc.contributor.icrauthorJames, Nicholasen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0